●HS-20089 (licensed to GSK as GSK5733584) is the first B7-H4-directed antibody-drug conjugate (ADC) to demonstrate promising efficacy in heavily pretreated patients with platinum-resistant ovarian cancer (PROC) who were not selected based on tumor B7-H4 expression, with a confirmed ORR of 48.5% and DoR of 6.8 months，a median PFS (mPFS) of 6.4 months and a mOS of 14.6 months at the dose of 4.8mg/kg.
● HS-20089 demonstrated a manageable safety profile and No new safety signal was observed.
● These clinical results support the further development of HS-20089 in patients with PROC and a phase 3 study is on-going (NCT06855069).
October 20, 2025
Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) today announced positive phase 2 study findings of HS-20089, a B7-H4-targeted Antibody-drug Conjugate, in patients with platinum-resistant ovarian cancer (PROC). The findings are being presented in a poster session at the European Society for Medical Oncology 2025 Annual Meeting (October 17-21, Berlin, Germany).
This was a multicenter, open-label, phase 2 study evaluating the efficacy, safety, pharmacokinetic profile, and immunogenicity of HS-20089 injection in patients with recurrent or metastatic ovarian and endometrial cancer. Eligible patients were enrolled to receive 4.8 mg/kg HS-20089 every 3 weeks. Although the samples were collected to test B7-H4 expression, patients were not selected based on B7-H4 expression levels. The primary endpoint was investigator-assessed objective response rate (ORR) according to RECIST v1.1. The results of Cohort 1 are reported and the data cut–off date was June 20th, 2025.
Study results showed:
● Heavily pretreated PROC patients：At data cut-off, 33 patients with high-grade serous ovarian cancer were enrolled and received at least one dose of HS-20089, comprising the safety set. All patients were heavily pretreated, with a median of 3 prior lines of anti-tumor therapy and 45.5% of patients had a platinum free interval of 3 months or less.. 72.7% patients had been treated with bevacizumab, and another 72.7% had received a PARP inhibitor.
● Promising primary results：The efficacy was analyzed in all patients who received treatment, with a median follow-up time of 11.5 months. Treatment with HS-20089 showed promising efficacy in patients with PROC, with a confirmed ORR of 48.5% and DoR of 6.8 months, a mPFS of 6.4 months and a mOS of 14.6 months. B7-H4 was found to be highly expressed in PROC, however, no no significant correlation was observed between B7-H4 expression levels and treatment response to HS -20089..
● Manageable safety profile: The observed safety profile of HS-20089 was consistent with data from the phase 1 study, with no signals of interstitial lung disease.
An encored oral presentation of the findings from HS-20089 will be delivered at the IGCS 2025 Annual Global Meeting, which is to be held at the Century City Conference Centre in Cape Town, South Africa, from November 5 to 7, 2025.
About HS-20089
HS-20089 is a B7-H4-targeted ADC self-developed by Hansoh Pharma. As of now, HS-20089 has entered phase III clinical research for the treatment of the platinum–resistant ovarian cancer indication in China and currently is also undergoing PoC clinical studies for the treatment of endometrial cancer and other solid tumors.
In October,2023,Hansoh Pharma entered into an exclusive license agreement with GlaxoSmithKline Intellectual Property (No.4) Limited (“GSK”), granting GSK an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture and commercialize the Product（also known as GSK5733584.GSK is advancing GSK5733584 through a global development programme, with Phase I trials underway globally that includes the BEHOLD-1 (NCT06431594) and BEHOLD-2 (NCT06796907) studies.
In May 2025, HS-20089 was approved by the NMPA as a Breakthrough-Therapy-Designated Drug, with the proposed indication for platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
About Ovarian Cancer
Ovarian cancer (OC) is one of the most prevalent gynecological malignancies. In 2022, approximately 324,603 new cases of ovarian cancer were diagnosed worldwide, making it the eighth most common malignancy among women. With around 206,956 deaths that year, ovarian cancer was the eighth leading cause of cancer-related mortality among female patients. In China, the incidence in 2022 was 61,060, with a mortality of 32,646[1].
The current standard treatment for ovarian cancer involves surgery combined with platinum-based chemotherapy. However, most advanced-stage patients relapse within 3 years and eventually develop drug resistance to platinum-based chemotherapy. The clinical treatment methods and efficacy for platinum-resistant recurrent ovarian cancer (PROC) remain extremely limited.
Recent Phase III randomized controlled trials show that the ORR for non-platinum monotherapy chemotherapy is 4%–15.9%, with a median PFS of 3.4–3.98 months. In patients who have received 1–2 lines of prior treatment, non-platinum chemotherapy combined with bevacizumab yields an ORR of 27.3%, extending the median PFS to 6.7 months and the median OS to 16.6 months. Despite a significant extension in PFS, no notable OS benefit is observed compared to non-platinum chemotherapy[2-6].This disease represents a major unmet clinical need, underscoring the urgent demand for more effective treatment approaches.
About ESMO
The ESMO Congress is a leading global platform uniting clinicians, researchers, patient advocates, journalists, and industry professionals in oncology.
ESMO 2025 will showcase groundbreaking research, innovative treatments, and foster collaboration to shape the future of cancer care.
About Hansoh Pharma
Hansoh Pharma is a leading innovation-driven pharmaceutical company headquartered in China. The company is committed to addressing significant unmet medical needs in oncology, central nervous system (CNS) disorders, metabolic diseases, and autoimmune conditions. Hansoh Pharma has launched seven innovative drugs that generate product sales in the PRC, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top three pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
Statements
1. This announcement is intended for healthcare professionals only and not for advertising purposes.
2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.
3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.
4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.
The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.
Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.
All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
References
[1]International Agency for Research on Cancer. (2024). Cancer TODAY: GLOBOCAN 2022 (version 1.1). Retrieved April 26, 2025, from Global Cancer Observatory
[2]Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al. Lancet Oncol. Jul 2021;22(7):1034-1046.
[3] Gaillard S, Oaknin A, Ray-Coquard I, et al. Gynecol Oncol. Nov 2021;163(2):237-245.
[4] Hamanishi J, Takeshima N, Katsumata N, et al. J Clin Oncol. Nov 20 2021;39(33):3671-3681.
[5] Pujade-Lauraine E, Hilpert F, Weber B, et al.
[6] Moore KN, Angelergues A, Konecny GE, et al. N Engl J Med. Dec 7 2023;389(23):2162-2174.
